Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breaking 340B: What Happens After Medicare Payment Cut?

Executive Summary

CMS’ reduced payment for drugs purchased at 340B prices went into effect January 1 – but still faces potential legal and legislative challenges. But the real question is what will happen if it sticks?


Related Content

Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
The Ups and Downs Of US Drug Pricing Policy
Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts